Genmab A/S GMAB.VI Stock
Genmab A/S Price Chart
Genmab A/S GMAB.VI Financial and Trading Overview
Genmab A/S stock price | 275.9 EUR |
Previous Close | 352.8 EUR |
Open | 355.7 EUR |
Bid | 360 EUR x N/A |
Ask | 362.9 EUR x N/A |
Day's Range | 352.8 - 355.7 EUR |
52 Week Range | 269.1 - 445.6 EUR |
Volume | 0 EUR |
Avg. Volume | 0 EUR |
Market Cap | 23.02B EUR |
Beta (5Y Monthly) | 0.683524 |
PE Ratio (TTM) | 32.818604 |
EPS (TTM) | 8.86 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
GMAB.VI Valuation Measures
Enterprise Value | -410995040 EUR |
Trailing P/E | 32.818604 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.5017726 |
Price/Book (mrq) | 0.8462846 |
Enterprise Value/Revenue | -0.027 |
Enterprise Value/EBITDA | -0.062 |
Trading Information
Genmab A/S Stock Price History
Beta (5Y Monthly) | 0.683524 |
52-Week Change | 31.10% |
S&P500 52-Week Change | 20.43% |
52 Week High | 445.6 EUR |
52 Week Low | 269.1 EUR |
50-Day Moving Average | 370.26 EUR |
200-Day Moving Average | 374.92 EUR |
GMAB.VI Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 65.26M |
Float | 64.42M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 49.71% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 34.46% |
Operating Margin (ttm) | 41.21% |
Gross Margin | 100.00% |
EBITDA Margin | 43.45% |
Management Effectiveness
Return on Assets (ttm) | 14.27% |
Return on Equity (ttm) | 21.17% |
Income Statement
Revenue (ttm) | 15.33B EUR |
Revenue Per Share (ttm) | 234.61 EUR |
Quarterly Revenue Growth (yoy) | 34.69% |
Gross Profit (ttm) | 14.6B EUR |
EBITDA | 6.66B EUR |
Net Income Avi to Common (ttm) | 5.28B EUR |
Diluted EPS (ttm) | 10.75 |
Quarterly Earnings Growth (yoy) | -51.39% |
Balance Sheet
Total Cash (mrq) | 24.54B EUR |
Total Cash Per Share (mrq) | 376.31 EUR |
Total Debt (mrq) | 829M EUR |
Total Debt/Equity (mrq) | 3.05 EUR |
Current Ratio (mrq) | 14.44 |
Book Value Per Share (mrq) | 416.881 |
Cash Flow Statement
Operating Cash Flow (ttm) | 6.56B EUR |
Levered Free Cash Flow (ttm) | 4.53B EUR |
Profile of Genmab A/S
Country | Austria |
State | N/A |
City | Copenhagen |
Address | Kalvebod Brygge 43 |
ZIP | 1560 |
Phone | 45 70 20 27 28 |
Website | https://www.genmab.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 1846 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Q&A For Genmab A/S Stock
What is a current GMAB.VI stock price?
Genmab A/S GMAB.VI stock price today per share is 275.9 EUR.
How to purchase Genmab A/S stock?
You can buy GMAB.VI shares on the Vienna exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genmab A/S?
The stock symbol or ticker of Genmab A/S is GMAB.VI.
Which industry does the Genmab A/S company belong to?
The Genmab A/S industry is Biotechnology.
How many shares does Genmab A/S have in circulation?
The max supply of Genmab A/S shares is 65.35M.
What is Genmab A/S Price to Earnings Ratio (PE Ratio)?
Genmab A/S PE Ratio is 31.13995600 now.
What was Genmab A/S earnings per share over the trailing 12 months (TTM)?
Genmab A/S EPS is 8.86 EUR over the trailing 12 months.
Which sector does the Genmab A/S company belong to?
The Genmab A/S sector is Healthcare.